-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $80

Benzinga·11/18/2026 14:58:47
Listen to the news
TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $68 to $80.